Clinical Trial

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Recruiting
View on ClinicalTrials.gov →
Summary
This observational study aims to assess the effect of once-weekly s.c. semaglutide 2.4 mg as an adjunct to a calorie-reduced diet and increased physical activity on weight loss, change in hunger, body composition, depression, and quality of life after 68 weeks of treatment in adolescents diagnosed with monogenic obesity in routine clinical care.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-10.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT07302802
Lead Sponsor Prof. Dr. Martin Wabitsch
Collaborators: Novo Nordisk A/S
Conditions Monogenic Obesity
Enrollment 70 participants
Start Date 2025-12-01
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-08